Targeting CCL11 in the treatment of ovarian cancer

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 2, 2010, Pages 157-167

  Nolen, Brian M ^a,b   Lokshin, Anna E ^a,b,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CCL11; CCR2; CCR3; CCR5; Chemokine network; Ovarian cancer; Targeted therapy

Indexed keywords

APLAVIROC; BERTILIMUMAB; BMS 741672; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EOTAXIN; F 1322; GSK 706769; INCB 009471; INDOLOPIPERIDINE DERIVATIVE; INTERLEUKIN 2; MARAVIROC; MLN 1202; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7B11; PF 00232798; PIPERIDINE DERIVATIVE; PRO 140; SB 328437; TPI ASM 8; UCB 35625; UNCLASSIFIED DRUG; VICRIVIROC;

ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG TARGETING; HUMAN; INFLAMMATION; LEUKOCYTE; MACROPHAGE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

CELL MOVEMENT; CHEMOKINE CCL11; FEMALE; HUMANS; LEUKOCYTES; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 74949111637     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903512983     Document Type: Review

References (96)

1. Boente MP, Schilder R, Ozols RF. Gynecological cancers. Cancer Chemother Biol Response Modif 1999;18:418-434
2. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19(1):3-10
3. Baker TR, Piver MS. Etiology, biology, and epidemiology of ovarian cancer. Semin Surg Oncol 1994;10(4):242-248
4. Garcia-Zepeda EA, Combadiere C, Rothenberg ME, et al. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and-3. J Immunol 1996;157(12):5613-5626
5. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2(4):449-456
6. Ponath PD, Qin S, Ringler DJ, et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996;97(3):604-612
7. Miyamasu M, Misaki Y, Yamaguchi M, et al. Regulation of human eotaxin generation by Th1-/Th2-derived cytokines. Int Arch Allergy Immunol 2000; 122;(Suppl 1):54-58
8. Matthews AN, Friend DS, Zimmermann N, et al. Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci USA 1998;95(11):6273-6278
9. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007;256(2):137-165
10. Beaulieu S, Robbiani DF, Du X, et al. Expression of a functional eotaxin (CC chemokine ligand 11) receptor CCR3 by human dendritic cells. J Immunol 2002;169(6):2925-2936
11. de Paulis A, Annunziato F, Di Gioia L, et al. Expression of the chemokine receptor CCR3 on human mast cells. Int Arch Allergy Immunol 2001;124(1-3):146-150
12. Heinemann A, Hartnell A, Stubbs VE, et al. Basophil responses to chemokines are regulated by both sequential and cooperative receptor signaling. J Immunol 2000;165(12):7224-7233
13. Daugherty BL, Siciliano SJ, DeMartino JA, et al. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996;183(5):2349-2354
14. Bandeira-Melo C, Herbst A, Weller PF. Eotaxins. Contributing to the diversity of eosinophil recruitment and activation. Am J Respir Cell Mol Biol 2001;24(6):653-657
15. Ogilvie P, Bardi G, Clark-Lewis I, et al. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 2001;97(7):1920-1924
16. Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 2000;6(1):20-27
17. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 2004;113(1):11-28, quiz 29
18. Emanuele E, Falcone C, D'Angelo A, et al. Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis 2006;186(1):140-145
19. Mir A, Minguez M, Tatay J, et al. Elevated serum eotaxin levels in patients with inflammatory bowel disease. Am J Gastroenterol 2002;97(6):1452-1457
20. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001;345(11):833-835
21. Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev 2006;58(8):962-974
22. Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. Leuk Lymphoma 2000;38(3-4):363-371
23. Jöhrer K, Zelle-Rieser C, Perathoner A, et al. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res 2005;11(7):2459-2465
24. Wågsäter D, Löfgren S, Hugander A, et al. Analysis of single nucleotide polymorphism in the promoter and protein expression of the chemokine eotaxin-1 in colorectal cancer patients. World J Surg Oncol 2007;5:84. Published online 31 July 2007, doi: 10.1186/1477-7819-5-84 (Pubitemid 47382036)
25. Zhang Y, Yao F, Yao X, et al. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24-phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 2009;21(4):1113-1121
26. Chinni SR, Sivalogan S, Dong Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006;66(1):32-48
27. Jiang YP, Wu XH, Shi B, et al. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol 2006;103(1):226-233
28. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000;6(8):3282-3289
29. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008;267(2):271-285
30. Lu Y, Cai Z, Xiao G, et al. CCR2 expression correlates with prostate cancer progression. J Cell Biochem 2007;101(3):676-685
31. González HE, Leiva A, Tobar H, et al. Altered chemokine receptor expression in papillary thyroid cancer. Thyroid 2009;19(9):957-965
32. Negus RP, Stamp GW, Relf MG, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995;95(5):2391-2396
33. Milliken D, Scotton C, Raju S, et al. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002;8(4):1108-1114
34. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997;150(5):1723-1734
35. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-949
36. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-213
37. Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer-much more than directing cell movement. Int J Dev Biol 2004;48(5-6):489-496
38. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 2002;12(2):113-120
39. Wong KH, Negishi H, Adashi EY. Expression, hormonal regulation, and cyclic variation of chemokines in the rat ovary: key determinants of the intraovarian residence of representatives of the white blood cell series. Endocrinology 2002;143(3):784-791
40. Hornung D, Dohrn K, Sotlar K, et al. Localization in tissues and secretion of eotaxin by cells from normal endometrium and endometriosis. J Clin Endocrinol Metab 2000;85(7):2604-2608
41. Levina V, Nolen BM, Marrangoni AM, et al. Role of eotaxin-1 signaling in ovarian cancer. Clin Cancer Res 2009;15(8):2647-2656
42. Youngs SJ, Ali SA, Taub DD, Rees RC. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 1997;71(2):257-266
43. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62(20):5930-5938
44. Menzies-Gow A, Ying S, Sabroe I, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early-and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 2002;169(5):2712-2718
45. Hohki G, Terada N, Hamano N, et al. The effects of eotaxin on the surface adhesion molecules of endothelial cells and on eosinophil adhesion to microvascular endothelial cells. Biochem Biophys Res Commun 1997;241(1):136-141
46. Kodali R, Hajjou M, Berman AB, et al. Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells. Cardiovasc Res 2006;69(3):706-715
47. Kampen GT, Stafford S, Adachi T, et al. Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 2000;95(6):1911-1917
48. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860- 867
49. Haley KJ, Sunday ME, Porrata Y, et al. Ontogeny of the eotaxins in human lung. Am J Physiol Lung Cell Mol Physiol 2008;294(2):L214-24
50. Peled A, Gonzalo JA, Lloyd C, Gutierrez-Ramos JC. The chemotactic cytokine eotaxin acts as a granulocyte-macrophage colony-stimulating factor during lung inflammation. Blood 1998;91(6):1909-1916
51. Salcedo R, Ponce ML, Young HA, et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000;96(1):34-40
52. Salcedo R, Young HA, Ponce ML, et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol 2001;166(12):7571-7578
53. Beck LA, Tancowny B, Brummet ME, et al. Functional analysis of the chemokine receptor CCR3 on airway epithelial cells. J Immunol 2006;177(5):3344-3354
54. Ouyang Z, Osuga Y, Hirota Y, et al. Interleukin-4 induces expression of eotaxin in endometriotic stromal cells. Fertil Steril 2009: published online 31 March 2009, doi: 10.1016/j.fertnstert.2009.01.129
55. Barbero S, Bonavia R, Bajetto A, et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003;63(8):1969-1974
56. Farahi N, Cowburn AS, Upton PD, et al. Eotaxin-1/CC chemokine ligand 11: a novel eosinophil survival factor secreted by human pulmonary artery endothelial cells. J Immunol 2007;179(2):1264-1273
57. Ryazantseva NV, Novitskii VV, Litvinova LS, et al. Effect of recombinant interleukin-5, interleukin-3, and eotaxin on apoptosis in eosinophilic granulocytes. Bull Exp Biol Med 2007;143(4):395-398
58. Youn BS, Kim YJ, Mantel C, et al. Blocking of c-FLIPL-independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction. Blood 2001;98(4):925-933
59. Rivoltini L, Viggiano V, Spinazzè S, et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 1993;l54(1):8-15
60. Samoszuk M. Eosinophils and human cancer. Histol Histopathol 1997;12(3):807-812
61. Enblad G, Sundstrom C, Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 1993;11(4):187-193
62. Toth J, Dworak O, Sugar J. Eosinophil predominance in Hodgkin's disease. Cancer Res Clin Oncol 1977;89(1):107-111
63. Grigolato PG, Favret M, Benetti A, et al. A case of gastric carcinoma with massive eosinophilia and squamous differentiation. Histochemical, immunohistochemical and ultrastructural aspects. Arch Anat Cytol Pathol 1990;38(1-2):43-47
64. Moroni M, Porta C, De Amici M, et al. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients. Haematologica 2000;85(3):298-303
65. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000;88(7):1544-1548
66. Mattes J, Hulett M, Xie W, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003;197(3):387-393
67. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57(3):503-512
68. Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007;178(7):4222-4229
69. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992;257(5069):548-551
70. Nathan CF, Klebanoff SJ. Augmentation of spontaneous macrophage-mediated cytolysis by eosinophil peroxidase. J Exp Med 1982;155(5):1291-1308
71. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001;193(6):F23-6
72. Karagiannis SN, Bracher MG, Hunt J, et al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007;179(5):2832-2843
73. Zhu XQ, Lv JQ, Lin Y, et al. Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells. Gynecol Oncol 2007;105(3):650-656
74. Kondo K, Muramatsu M, Okamoto Y, et al. Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J Surg Oncol 2006;93(1):36-42, discussion 42-43
75. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000;88(12):2686-2692
76. Chan JK, Magistris A, Loizzi V, et al. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecol Oncol 2005;99(1):20-25
77. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008;222:101-116
78. Dong HP, Elstrand MB, Holth A, et al. NK-and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006;125(3):451-458
79. Eisenthal A, Polyvkin N, Bramante-Schreiber L, et al. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum Pathol 2001;32(8):803-807
80. den Ouden M, Ubachs JM, Stoot JE, van Wersch JW. Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol 1997;72(1):73-77
81. Vlad AM, Budiu RA, Lenzner DE, et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010;59:293-301
82. Rand TH, Silberstein DS, Kornfeld H, Weller PF. Human eosinophils express functional interleukin 2 receptors. J Clin Invest 1991;88(3):825-832
83. Lorena SC, Oliveira DT, Dorta RG, et al. Eotaxin expression in oral squamous cell carcinomas with and without tumour associated tissue eosinophilia. Oral Dis 2003;9(6):279-283
84. Samoszuk M, Deng T, Hamamura MJ, et al. Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice. Am J Pathol 2004;165(2):449-456
85. Stellato C, Matsukura S, Fal A, et al. Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J Immunol 1999;163(10):5624-5632
86. Main S, Handy R, Wilton J, et al. A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther 2006;319(3):1395-1404
87. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 2003;111(2):227-242, quiz 243
88. Gonzalo JA, Lloyd CM, Kremer L, et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. J Clin Invest 1996;98(10):2332-2345
89. Humbles AA, Conroy DM, Marleau S, et al. Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease: analysis in a guinea pig model in vivo. J Exp Med 1997;186(4):601-612
90. Heath H, Qin S, Rao P, et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997;99(2):178-184
91. White JR, Lee JM, Dede K, et al. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J Biol Chem 2000;275(47):36626-36631
92. Mochizuki A, Tamura N, Yatabe Y, et al. Suppressive effects of F-1322 on the antigen-induced late asthmatic response and pulmonary eosinophilia in guinea pigs. Eur J Pharmacol 2001;430(1):123-133
93. Vergunst CE, Gerlag DM, Lopatinskaya L, et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008;58(7):1931-1939
94. Bristol-Myers Squibb Clinical Trial Registry-Metabolics; Available from: http://ctr.bms.com/OneBmsCtd/InitTrialAction.do?linkname=Metabolics& type=pharma&sortby=default (last accessed 12 March 2009)
95. Witherington J, Bordas V, Cooper DG, et al. Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists. Bioorg Med Chem Lett 2001;11(16):2177-2180
96. Emmelkamp JM, Rockstroh JK. Maraviroc, risks and benefits: a review of the clinical literature. Expert Opin Drug Saf 2008;7(5):559-569